prednisolone has been researched along with Kawasaki Disease in 54 studies
Prednisolone: A glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states.
prednisolone : A glucocorticoid that is prednisone in which the oxo group at position 11 has been reduced to the corresponding beta-hydroxy group. It is a drug metabolite of prednisone.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prednisolone (PSL) has been suggested to be useful for the treatment of Kawasaki disease (KD) resistant to i." | 9.24 | Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease. ( Akiyama, N; Asakura, I; Fukuoka, T; Harazaki, M; Iwashima, S; Kamimaki, T; Kimura, M; Meguro, T; Morishita, H; Ohkawara, I; Sakai, H; Seto, S; Shimomura, M; Tsurui, S, 2017) |
| " Patients with severe Kawasaki disease were randomly assigned by a minimisation method to receive either intravenous immunoglobulin (2 g/kg for 24 h and aspirin 30 mg/kg per day) or intravenous immunoglobulin plus prednisolone (the same intravenous immunoglobulin regimen as the intravenous immunoglobulin group plus prednisolone 2 mg/kg per day given over 15 days after concentrations of C-reactive protein normalised)." | 9.16 | Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. ( Arakawa, H; Fukazawa, R; Furuno, K; Fuse, S; Hamaoka, K; Hara, S; Hara, T; Ichida, F; Kato, T; Kobayashi, T; Miura, M; Morikawa, A; Nakamura, T; Nomura, Y; Ogawa, C; Ogawa, S; Otani, T; Saji, T; Seki, M; Takatsuki, S; Takeuchi, K; Tokunaga, H, 2012) |
| "Prednisolone therapy for acute phase Kawasaki disease had been considered to be controversial for several decades." | 8.90 | [Prednisolone therapy for Kawasaki disease]. ( Arakawa, H; Kobayashi, T, 2014) |
| " Patients who were febrile at diagnosis received primary IVIG (2 g/kg per 24 h) and oral aspirin (30 mg/kg per day) until the fever resolved, followed by oral aspirin (5 mg/kg per day) for 2 months after Kawasaki disease onset." | 7.88 | Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study. ( Chiga, M; Hori, N; Kaneko, T; Komiyama, O; Matsushima, T; Misawa, M; Miura, M; Miyata, K; Morikawa, Y; Nakazawa, M; Obonai, T; Sakakibara, H; Takahashi, T; Tamame, T; Tsuchihashi, T; Yamagishi, H; Yamashita, Y, 2018) |
| "To identify the prevalence of bradycardia associated with use of prednisolone in patients with Kawasaki disease and analyze the association between bradycardia and responsiveness to intravenous immunoglobulin (IVIG)." | 7.85 | Bradycardia Associated with Prednisolone in Children with Severe Kawasaki Disease. ( Miura, M; Morikawa, Y; Nagakura, A; Sakakibara, H, 2017) |
| "Combination treatment with intravenous immunoglobulin (IVIG) plus prednisolone, newly designed for children with severe Kawasaki disease (KD), reduces coronary artery abnormalities significantly." | 7.81 | High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone. ( Goto, M; Hasegawa, Y; Kikunaga, K; Miura, M; Miyagawa, N, 2015) |
| "We reported previously that intravenous immunoglobulin (IVIG) plus prednisolone for initial therapy for Kawasaki disease (KD) prevented coronary artery abnormalities (CAA) more effectively than IVIG alone." | 7.75 | Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease. ( Arakawa, H; Inoue, Y; Kobayashi, T; Miura, M; Morikawa, A; Ogawa, S; Otani, T; Saji, T; Sonobe, T; Takeuchi, K, 2009) |
| "We report on 7 patients with severe, complicated Kawasaki disease treated with oral prednisolone, after apparently unsuccessful intravenous immunoglobulin treatment." | 7.70 | Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. ( Dale, RC; Daw, S; Dillon, MJ; Saleem, MA, 2000) |
| " We were unable to draw any conclusions regarding acute coronary syndromes, mortality, or length of hospital stay, or for the comparison IVIG versus prednisolone." | 5.41 | Intravenous immunoglobulin for the treatment of Kawasaki disease. ( Broderick, C; Ito, S; Kobayashi, S; Kobayashi, T; Suto, M, 2023) |
| "Prednisolone (PSL) has been suggested to be useful for the treatment of Kawasaki disease (KD) resistant to i." | 5.24 | Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease. ( Akiyama, N; Asakura, I; Fukuoka, T; Harazaki, M; Iwashima, S; Kamimaki, T; Kimura, M; Meguro, T; Morishita, H; Ohkawara, I; Sakai, H; Seto, S; Shimomura, M; Tsurui, S, 2017) |
| " Patients with severe Kawasaki disease were randomly assigned by a minimisation method to receive either intravenous immunoglobulin (2 g/kg for 24 h and aspirin 30 mg/kg per day) or intravenous immunoglobulin plus prednisolone (the same intravenous immunoglobulin regimen as the intravenous immunoglobulin group plus prednisolone 2 mg/kg per day given over 15 days after concentrations of C-reactive protein normalised)." | 5.16 | Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial. ( Arakawa, H; Fukazawa, R; Furuno, K; Fuse, S; Hamaoka, K; Hara, S; Hara, T; Ichida, F; Kato, T; Kobayashi, T; Miura, M; Morikawa, A; Nakamura, T; Nomura, Y; Ogawa, C; Ogawa, S; Otani, T; Saji, T; Seki, M; Takatsuki, S; Takeuchi, K; Tokunaga, H, 2012) |
| "Prednisolone therapy for acute phase Kawasaki disease had been considered to be controversial for several decades." | 4.90 | [Prednisolone therapy for Kawasaki disease]. ( Arakawa, H; Kobayashi, T, 2014) |
| " Patients who were febrile at diagnosis received primary IVIG (2 g/kg per 24 h) and oral aspirin (30 mg/kg per day) until the fever resolved, followed by oral aspirin (5 mg/kg per day) for 2 months after Kawasaki disease onset." | 3.88 | Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study. ( Chiga, M; Hori, N; Kaneko, T; Komiyama, O; Matsushima, T; Misawa, M; Miura, M; Miyata, K; Morikawa, Y; Nakazawa, M; Obonai, T; Sakakibara, H; Takahashi, T; Tamame, T; Tsuchihashi, T; Yamagishi, H; Yamashita, Y, 2018) |
| "To identify the prevalence of bradycardia associated with use of prednisolone in patients with Kawasaki disease and analyze the association between bradycardia and responsiveness to intravenous immunoglobulin (IVIG)." | 3.85 | Bradycardia Associated with Prednisolone in Children with Severe Kawasaki Disease. ( Miura, M; Morikawa, Y; Nagakura, A; Sakakibara, H, 2017) |
| "Combination treatment with intravenous immunoglobulin (IVIG) plus prednisolone, newly designed for children with severe Kawasaki disease (KD), reduces coronary artery abnormalities significantly." | 3.81 | High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone. ( Goto, M; Hasegawa, Y; Kikunaga, K; Miura, M; Miyagawa, N, 2015) |
| "We reported previously that intravenous immunoglobulin (IVIG) plus prednisolone for initial therapy for Kawasaki disease (KD) prevented coronary artery abnormalities (CAA) more effectively than IVIG alone." | 3.75 | Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease. ( Arakawa, H; Inoue, Y; Kobayashi, T; Miura, M; Morikawa, A; Ogawa, S; Otani, T; Saji, T; Sonobe, T; Takeuchi, K, 2009) |
| "Six patients with Kawasaki disease (KD) were treated with prednisolone (1 to 2 mg/kg/day) for 3 days (from days 10 to 12 after the onset of the illness) after apparently unsuccessful treatment with intravenous immunoglobulin (IVIG, 2 g/kg/dose and additional 1 g/kg/dose)." | 3.73 | Standard-dose and short-term corticosteroid therapy in immunoglobulin-resistant Kawasaki disease. ( Kawamura, Y; Nakatani, K; Takeshita, S; Tokutomi, T; Tsujimoto, H, 2005) |
| "We report on 7 patients with severe, complicated Kawasaki disease treated with oral prednisolone, after apparently unsuccessful intravenous immunoglobulin treatment." | 3.70 | Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. ( Dale, RC; Daw, S; Dillon, MJ; Saleem, MA, 2000) |
| "Ninety-two patients with Kawasaki disease were treated with five different types of drug therapy: a steroid preparation (prednisolone), aspirin, an antibiotic, a combination of steroid plus aspirin, and a combination of steroid plus warfarin." | 3.66 | Kawasaki disease: effect of treatment on coronary artery involvement. ( Kato, H; Koike, S; Yokoyama, T, 1979) |
| "Although there is ample evidence that Kawasaki disease (KD) is associated with vascular inflammation, few studies have addressed the influence of oxidative stress." | 2.77 | Regulation of oxidative stress in patients with Kawasaki disease. ( Arakawa, H; Inoue, Y; Kobayashi, T; Matsuda, S; Mochizuki, H; Sekine, K; Suganuma, E, 2012) |
| "Serum from patients with coronary aneurysms was less active in stimulating HUVEC tube formation than serum from patients without coronary aneurysms or febrile controls." | 2.73 | Impairment of angiogenic activity in the serum from patients with coronary aneurysms due to Kawasaki disease. ( Hamada, H; Higashi, K; Honda, T; Kanazawa, M; Kohno, Y; Terai, M, 2007) |
| "A total of 277 patients with Kawasaki disease were included in this study." | 1.72 | Stratified therapy for Kawasaki disease using a new scoring system to predict the response to a lower dose of intravenous immunoglobulin therapy. ( Hirakubo, Y; Ichihashi, K; Makita, E; Matsuura, M; Nonaka, K; Sugawara, D; Yamashita, S, 2022) |
| "We describe a case of intussusception followed by KD in a 3-year-old boy." | 1.62 | A Case of Kawasaki Disease with Intussusception. ( Abe, M; Asano, T; Fujita, A; Fukunaga, R; Ito, Y; Matsui, R; Miyatake-Sudoh, C; Ueharu, K; Yoshida, K, 2021) |
| "Thrombocytopenia was seen in 11 patients." | 1.62 | Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India. ( Gupta, A; Jindal, AK; Johnson, N; Pilania, RK; Prithvi, A; Rawat, A; Singh, S; Suri, D; Vignesh, P, 2021) |
| "Predominant conditions included juvenile idiopathic arthritis (JIA), juvenile systemic lupus erythematosus (JSLE) and juvenile dermatomyositis (JDM)." | 1.56 | Spectrum of paediatric rheumatic disorders at a tertiary hospital in Tanzania. ( Furia, FF; Godfrey, E; Mwamanenge, N; Swai, P, 2020) |
| "We report a 10-month-old infant with Kawasaki disease who was treated with high-dose IVIg and developed severe HA." | 1.46 | Severe Hemolytic Anemia Following Intravenous Immunoglobulin in an Infant With Kawasaki Disease. ( Inaba, A; Kurano, T; Nakayama, H; Soebijanto, K; Sonoda, M; Tocan, V, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (11.11) | 18.7374 |
| 1990's | 4 (7.41) | 18.2507 |
| 2000's | 10 (18.52) | 29.6817 |
| 2010's | 22 (40.74) | 24.3611 |
| 2020's | 12 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Lin, SY | 1 |
| He, L | 1 |
| Xie, LP | 1 |
| Wang, Y | 1 |
| Lin, YX | 1 |
| Cao, YY | 1 |
| Yan, WL | 1 |
| Liu, F | 1 |
| Huang, GY | 1 |
| Broderick, C | 1 |
| Kobayashi, S | 1 |
| Suto, M | 1 |
| Ito, S | 1 |
| Kobayashi, T | 17 |
| Okada, S | 1 |
| Hirano, R | 1 |
| Okazaki-Emi, S | 1 |
| Fukunaga, S | 1 |
| Ishikawa, Y | 1 |
| Furia, FF | 1 |
| Godfrey, E | 1 |
| Mwamanenge, N | 1 |
| Swai, P | 1 |
| Ueharu, K | 1 |
| Asano, T | 1 |
| Fukunaga, R | 1 |
| Matsui, R | 1 |
| Yoshida, K | 1 |
| Miyatake-Sudoh, C | 1 |
| Abe, M | 1 |
| Fujita, A | 1 |
| Ito, Y | 1 |
| Pilania, RK | 1 |
| Jindal, AK | 1 |
| Johnson, N | 1 |
| Prithvi, A | 1 |
| Vignesh, P | 1 |
| Suri, D | 1 |
| Rawat, A | 1 |
| Gupta, A | 1 |
| Singh, S | 1 |
| Uda, K | 1 |
| Okita, K | 1 |
| Soneda, K | 1 |
| Taniguchi, K | 1 |
| Horikoshi, Y | 1 |
| Sakai, H | 2 |
| Iwashima, S | 2 |
| Sano, S | 1 |
| Akiyama, N | 2 |
| Nagata, E | 1 |
| Harazaki, M | 2 |
| Fukuoka, T | 2 |
| Iio, K | 1 |
| Sakakibara, H | 3 |
| Ueno, K | 2 |
| Nomura, Y | 3 |
| Morita, Y | 2 |
| Kawano, Y | 2 |
| Yoshikane, Y | 1 |
| Okuma, Y | 1 |
| Miyamoto, T | 2 |
| Hashimoto, J | 1 |
| Fukazawa, R | 2 |
| Kato, T | 2 |
| Takeda, A | 1 |
| Suda, K | 1 |
| Matsushita, T | 1 |
| Hiroe, M | 1 |
| Imanaka-Yoshida, K | 1 |
| Matsuura, M | 1 |
| Sugawara, D | 1 |
| Makita, E | 1 |
| Hirakubo, Y | 1 |
| Nonaka, K | 1 |
| Yamashita, S | 1 |
| Ichihashi, K | 1 |
| Morita, A | 1 |
| Imagawa, K | 1 |
| Ishiodori, T | 1 |
| Tagawa, M | 1 |
| Takada, H | 1 |
| Nagakura, A | 1 |
| Morikawa, Y | 2 |
| Miura, M | 5 |
| Okubo, Y | 1 |
| Michihata, N | 1 |
| Morisaki, N | 1 |
| Sundel, RP | 1 |
| Matsui, H | 1 |
| Fushimi, K | 1 |
| Yasunaga, H | 1 |
| Miyata, K | 1 |
| Kaneko, T | 1 |
| Matsushima, T | 1 |
| Misawa, M | 1 |
| Takahashi, T | 1 |
| Nakazawa, M | 1 |
| Tamame, T | 1 |
| Tsuchihashi, T | 1 |
| Yamashita, Y | 1 |
| Obonai, T | 1 |
| Chiga, M | 1 |
| Hori, N | 1 |
| Komiyama, O | 1 |
| Yamagishi, H | 1 |
| Burns, JC | 1 |
| Hoshino, S | 1 |
| Morikawa, A | 7 |
| Ikeda, K | 1 |
| Seki, M | 2 |
| Shimoyama, S | 1 |
| Ishii, Y | 1 |
| Suzuki, T | 2 |
| Nakajima, K | 1 |
| Sakamoto, N | 1 |
| Arakawa, H | 5 |
| Etoom, Y | 1 |
| Banihani, R | 1 |
| Finkelstein, Y | 1 |
| Goto, M | 1 |
| Miyagawa, N | 1 |
| Kikunaga, K | 1 |
| Hasegawa, Y | 1 |
| Eguchi, T | 1 |
| Masuda, K | 1 |
| Takeda, K | 1 |
| Sato, T | 1 |
| Norizuki, M | 1 |
| Kamata, Y | 1 |
| Nagatani, K | 1 |
| Kawarai Lefor, A | 1 |
| Minota, S | 1 |
| Nakagama, Y | 1 |
| Inuzuka, R | 1 |
| Hayashi, T | 1 |
| Shindo, T | 1 |
| Hirata, Y | 1 |
| Shimizu, N | 1 |
| Inatomi, J | 1 |
| Yokoyama, Y | 1 |
| Namai, Y | 1 |
| Oda, Y | 1 |
| Takamizawa, M | 1 |
| Harita, Y | 1 |
| Oka, A | 1 |
| Kimura, M | 1 |
| Asakura, I | 1 |
| Kamimaki, T | 1 |
| Ohkawara, I | 1 |
| Tsurui, S | 1 |
| Shimomura, M | 1 |
| Morishita, H | 1 |
| Meguro, T | 1 |
| Seto, S | 1 |
| Tocan, V | 1 |
| Inaba, A | 1 |
| Kurano, T | 1 |
| Sonoda, M | 1 |
| Soebijanto, K | 1 |
| Nakayama, H | 1 |
| Wardle, AJ | 1 |
| Connolly, GM | 1 |
| Seager, MJ | 1 |
| Tulloh, RM | 1 |
| Inoue, Y | 5 |
| Otani, T | 2 |
| Takeuchi, K | 3 |
| Saji, T | 2 |
| Sonobe, T | 1 |
| Ogawa, S | 2 |
| Lim, TC | 1 |
| Yeo, WS | 1 |
| Loke, KY | 1 |
| Quek, SC | 1 |
| Hayashi, M | 1 |
| Monma, F | 1 |
| Katagiri, Y | 1 |
| Kawaguchi, M | 1 |
| Jibiki, T | 1 |
| Kato, I | 1 |
| Shiohama, T | 1 |
| Abe, K | 1 |
| Anzai, S | 1 |
| Takeda, N | 1 |
| Yamaguchi, KI | 1 |
| Kanazawa, M | 2 |
| Kurosaki, T | 1 |
| Sekine, K | 1 |
| Mochizuki, H | 1 |
| Suganuma, E | 1 |
| Matsuda, S | 1 |
| Garweg, JG | 1 |
| Suter, C | 1 |
| Aebi-Ochsner, C | 1 |
| Villiger, R | 1 |
| Son, MB | 1 |
| Newburger, JW | 2 |
| Nakamura, T | 1 |
| Hara, T | 1 |
| Hamaoka, K | 2 |
| Fuse, S | 1 |
| Ichida, F | 1 |
| Ogawa, C | 1 |
| Furuno, K | 1 |
| Tokunaga, H | 1 |
| Takatsuki, S | 1 |
| Hara, S | 1 |
| Okada, Y | 3 |
| Shinohara, M | 4 |
| Tomomasa, T | 3 |
| Onouchi, Z | 1 |
| Sakata, K | 1 |
| Ozawa, S | 1 |
| Shiraishi, I | 1 |
| Itoi, T | 1 |
| Kiyosawa, N | 1 |
| Takeshita, S | 1 |
| Kawamura, Y | 1 |
| Nakatani, K | 1 |
| Tsujimoto, H | 1 |
| Tokutomi, T | 1 |
| Higashi, K | 1 |
| Terai, M | 1 |
| Hamada, H | 1 |
| Honda, T | 1 |
| Kohno, Y | 1 |
| Yamazaki-Nakashimada, MA | 1 |
| RamÃrez-Vargas, N | 1 |
| De Rubens-Figueroa, J | 1 |
| Kato, H | 2 |
| Ichinose, E | 1 |
| Sone, K | 2 |
| Kosuda, T | 1 |
| Gatenby, PA | 1 |
| Dale, RC | 1 |
| Saleem, MA | 1 |
| Daw, S | 1 |
| Dillon, MJ | 1 |
| Koike, S | 1 |
| Yokoyama, T | 1 |
| Elamin, AM | 1 |
| Ikpatt, NW | 1 |
| Ibia, EO | 1 |
| Kusakawa, S | 1 |
| Tatara, K | 1 |
| Hashimoto, Y | 1 |
| Yoshinoya, S | 1 |
| Aikawa, T | 1 |
| Mitamura, T | 1 |
| Miyoshi, Y | 1 |
| Muranaka, M | 1 |
| Yanase, Y | 1 |
| Kawasaki, T | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Efficacy of Immunoglobulin Plus Prednisolone in Reducing Coronary Artery Lesion in Patients With Kawasaki Disease: A Multicentre Randomised Controlled Trial[NCT04078568] | Phase 3 | 3,200 participants (Anticipated) | Interventional | 2020-01-15 | Recruiting | ||
| A Randomized Open-label Trial to Evaluate the Efficacy of Immunoglobulin Plus Steroid for Prevention of Coronary Artery Abnormalities in Taiwanese Refractory Kawasaki Disease (RAST Study)[NCT03200561] | Phase 3 | 100 participants (Anticipated) | Interventional | 2013-10-17 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for prednisolone and Kawasaki Disease
| Article | Year |
|---|---|
Intravenous immunoglobulin for the treatment of Kawasaki disease.
Topics: Acute Coronary Syndrome; Aspirin; Child; Fever; Humans; Immunoglobulins, Intravenous; Inflammation; | 2023 |
Kawasaki disease with dilatation of the common bile duct: A case report and review of literature.
Topics: Child, Preschool; Common Bile Duct; Dilatation, Pathologic; Glucocorticoids; Humans; Immunoglobulins | 2021 |
[Prednisolone therapy for Kawasaki disease].
Topics: Acute Disease; Anti-Inflammatory Agents; Humans; Immunoglobulins, Intravenous; Mucocutaneous Lymph N | 2014 |
Corticosteroids for the treatment of Kawasaki disease in children.
Topics: Acute Disease; Adolescent; Adrenal Cortex Hormones; Child; Child, Preschool; Coronary Artery Disease | 2017 |
Vasculitis--diagnosis and treatment.
Topics: Adult; Anti-Inflammatory Agents; Antibodies, Antineutrophil Cytoplasmic; Child; Female; Giant Cell A | 1999 |
7 trials available for prednisolone and Kawasaki Disease
| Article | Year |
|---|---|
Effects of immunoglobulin plus prednisolone in reducing coronary artery lesions in patients with Kawasaki disease: study protocol for a phase III multicenter, open-label, blinded-endpoints randomized controlled trial.
Topics: Child; Child, Preschool; Clinical Trials, Phase III as Topic; Coronary Vessels; Humans; Immunoglobul | 2021 |
Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease.
Topics: Adolescent; Anti-Inflammatory Agents; Child; Child, Preschool; Drug Administration Schedule; Drug Th | 2017 |
Regulation of oxidative stress in patients with Kawasaki disease.
Topics: Anti-Inflammatory Agents; Child, Preschool; Combined Modality Therapy; Female; Glutathione; Humans; | 2012 |
Efficacy of immunoglobulin plus prednisolone for prevention of coronary artery abnormalities in severe Kawasaki disease (RAISE study): a randomised, open-label, blinded-endpoints trial.
Topics: Anti-Inflammatory Agents; Aspirin; Child, Preschool; Coronary Artery Disease; Coronary Vessel Anomal | 2012 |
Effect of corticosteroids in addition to intravenous gamma globulin therapy on serum cytokine levels in the acute phase of Kawasaki disease in children.
Topics: Acute-Phase Reaction; Anti-Inflammatory Agents; Child; Child, Preschool; Cytokines; Drug Therapy, Co | 2003 |
A multicenter prospective randomized trial of corticosteroids in primary therapy for Kawasaki disease: clinical course and coronary artery outcome.
Topics: Child; Child, Preschool; Coronary Aneurysm; Drug Therapy, Combination; Female; Glucocorticoids; Huma | 2006 |
Impairment of angiogenic activity in the serum from patients with coronary aneurysms due to Kawasaki disease.
Topics: Angiogenesis Inhibitors; Anticoagulants; Aspirin; Cell Proliferation; Cells, Cultured; Child; Child, | 2007 |
42 other studies available for prednisolone and Kawasaki Disease
| Article | Year |
|---|---|
Erythema multiforme- and not erythema multiforme-like rashes in Kawasaki disease.
Topics: Child, Preschool; Chlorpheniramine; Erythema Multiforme; Glucocorticoids; Humans; Immunoglobulins, I | 2019 |
Spectrum of paediatric rheumatic disorders at a tertiary hospital in Tanzania.
Topics: Adolescent; Anemia; Antibodies, Antinuclear; Antirheumatic Agents; Arthralgia; Arthritis, Juvenile; | 2020 |
A Case of Kawasaki Disease with Intussusception.
Topics: Age Factors; Aspirin; Child, Preschool; Colon; Colonic Diseases; Humans; Immunoglobulins, Intravenou | 2021 |
Macrophage activation syndrome in children with Kawasaki disease: an experience from a tertiary care hospital in northwest India.
Topics: Child; Child, Preschool; Coronary Aneurysm; Female; Glucocorticoids; Humans; Immunoglobulins, Intrav | 2021 |
Kawasaki disease following coronavirus disease 2019 with prolonged fecal viral shedding.
Topics: Anti-Inflammatory Agents; COVID-19; Feces; Humans; Immunoglobulins, Intravenous; Immunologic Factors | 2021 |
Targeted Use of Prednisolone with Intravenous Immunoglobulin for Kawasaki Disease.
Topics: Child, Preschool; Cohort Studies; Female; Humans; Immunoglobulins, Intravenous; Infant; Infliximab; | 2021 |
Pneumatosis Intestinalis in a Febrile 11-Month-Old Boy.
Topics: Fever; Gases; Glucocorticoids; Humans; Immunoglobulins, Intravenous; Infant; Male; Mucocutaneous Lym | 2021 |
Prednisolone Suppresses the Extracellular Release of HMGB-1 and Associated Inflammatory Pathways in Kawasaki Disease.
Topics: Anti-Inflammatory Agents; Cells, Cultured; Coronary Vessels; Endothelial Cells; HMGB1 Protein; Human | 2021 |
Serum tenascin-C predicts resistance to steroid combination therapy in high-risk Kawasaki disease: a multicenter prospective cohort study.
Topics: Aspirin; Biomarkers; Child; Child, Preschool; Cohort Studies; Drug Combinations; Drug Resistance; Fe | 2021 |
Stratified therapy for Kawasaki disease using a new scoring system to predict the response to a lower dose of intravenous immunoglobulin therapy.
Topics: Coronary Vessels; Humans; Immunoglobulins, Intravenous; Infant; Mucocutaneous Lymph Node Syndrome; P | 2022 |
Bradycardia Associated with Prednisolone in Children with Severe Kawasaki Disease.
Topics: Bradycardia; Child, Preschool; Cohort Studies; Drug Therapy, Combination; Female; Glucocorticoids; H | 2017 |
Association Between Dose of Glucocorticoids and Coronary Artery Lesions in Kawasaki Disease.
Topics: Child, Preschool; Coronary Artery Disease; Dose-Response Relationship, Drug; Female; Glucocorticoids | 2018 |
Efficacy and safety of intravenous immunoglobulin plus prednisolone therapy in patients with Kawasaki disease (Post RAISE): a multicentre, prospective cohort study.
Topics: Aspirin; Child, Preschool; Drug Therapy, Combination; Female; Fever; Glucocorticoids; Humans; Immuno | 2018 |
Kawasaki disease: an essential comparison of coronary artery aneurysm criteria.
Topics: Anti-Inflammatory Agents; Child; Cohort Studies; Coronary Vessels; Echocardiography; Female; Fever; | 2018 |
Efficacy of intravenous immunoglobulin combined with prednisolone following resistance to initial intravenous immunoglobulin treatment of acute Kawasaki disease.
Topics: Acute Disease; Child, Preschool; Drug Resistance; Drug Therapy, Combination; Female; Glucocorticoids | 2013 |
Critical review of: Efficacy of immunoglobulin plus prednisone for prevention of coronary artery prednisolone for prevention of coronary abnormalities in severe Kawasaki disease (RAISE study): a randomized, open-label, blinded-endpoints trial.
Topics: Anti-Inflammatory Agents; Coronary Artery Disease; Coronary Vessel Anomalies; Female; Humans; Immuno | 2013 |
Guidelines for medical treatment of acute Kawasaki disease: report of the Research Committee of the Japanese Society of Pediatric Cardiology and Cardiac Surgery (2012 revised version).
Topics: Algorithms; Antibodies, Monoclonal; Anticoagulants; Child; Glucocorticoids; Glycoproteins; Humans; I | 2014 |
High incidence of adrenal suppression in children with Kawasaki disease treated with intravenous immunoglobulin plus prednisolone.
Topics: Adrenal Glands; Adrenal Insufficiency; Adrenocorticotropic Hormone; Anti-Inflammatory Agents; Child; | 2015 |
Circulating platelet-neutrophil aggregates play a significant role in Kawasaki disease.
Topics: Aspirin; beta-Thromboglobulin; Blood Platelets; Child, Preschool; Coronary Vessels; Drug Resistance; | 2015 |
Adult Kawasaki-like syndrome with eosinophilia and tenosynovitis in a patient with human immunodeficiency virus infection.
Topics: Adult; Antiviral Agents; Eosinophilia; HIV Infections; Humans; Male; Mucocutaneous Lymph Node Syndro | 2015 |
Fever pattern and C-reactive protein predict response to rescue therapy in Kawasaki disease.
Topics: C-Reactive Protein; Child, Preschool; Drug Therapy, Combination; Female; Fever; Follow-Up Studies; G | 2016 |
Severe Hemolytic Anemia Following Intravenous Immunoglobulin in an Infant With Kawasaki Disease.
Topics: Anemia, Hemolytic, Autoimmune; Autoantibodies; Erythrocyte Transfusion; Hemagglutination Tests; Huma | 2017 |
Risk stratification in the decision to include prednisolone with intravenous immunoglobulin in primary therapy of Kawasaki disease.
Topics: Analysis of Variance; Child, Preschool; Coronary Artery Disease; Female; Humans; Immunoglobulins, In | 2009 |
Bilateral facial nerve palsy in Kawasaki disease.
Topics: Anti-Inflammatory Agents; Aspirin; Child; Facial Nerve Diseases; Facial Paralysis; Humans; Immunoglo | 2009 |
Linear immunoglobulin A bullous dermatosis associated with herpes simplex virus infection and Kawasaki disease.
Topics: Acyclovir; Aspirin; Basement Membrane; Dapsone; Glycoproteins; Herpes Simplex; Humans; Immunization, | 2010 |
Intravenous immune globulin plus corticosteroids in refractory Kawasaki disease.
Topics: Acute Disease; Child, Preschool; Drug Administration Schedule; Drug Therapy, Combination; Female; Gl | 2011 |
Macular oedema in Kawasaki syndrome.
Topics: Aspirin; Child; Drug Therapy, Combination; Fibrinolytic Agents; Glucocorticoids; Humans; Immunoglobu | 2012 |
Management of Kawasaki disease: corticosteroids revisited.
Topics: Anti-Inflammatory Agents; Coronary Artery Disease; Coronary Vessel Anomalies; Female; Humans; Immuno | 2012 |
Long-term changes in coronary artery aneurysms in patients with Kawasaki disease: comparison of therapeutic regimens.
Topics: Acute Disease; Aspirin; Coronary Aneurysm; Coronary Stenosis; gamma-Globulins; Humans; Longitudinal | 2005 |
Standard-dose and short-term corticosteroid therapy in immunoglobulin-resistant Kawasaki disease.
Topics: Child; Child, Preschool; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resist | 2005 |
Treatment of Kawasaki disease.
Topics: Adrenal Cortex Hormones; Coronary Disease; Humans; Mucocutaneous Lymph Node Syndrome; Prednisolone; | 2007 |
Chronic granulomatous disease associated with atypical Kawasaki disease.
Topics: Comorbidity; Drug Therapy, Combination; Glucocorticoids; Granulomatous Disease, Chronic; Humans; Imm | 2008 |
[Therapy of Kawasaki disease in the acute phase: steroid and aspirin therapy].
Topics: Acute Disease; Age Factors; Aneurysm; Aspirin; Child, Preschool; Coronary Disease; Humans; Infant; M | 1983 |
Treatment of Kawasaki disease with corticosteroid.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Drug Therapy, Combinatio | 1996 |
Treatment of Kawasaki disease: corticosteroids revisited.
Topics: Child; Contraindications; Coronary Aneurysm; Glucocorticoids; Humans; Immunoglobulins, Intravenous; | 1999 |
Corticosteroids in the treatment of the acute phase of Kawasaki disease.
Topics: Acute Disease; Aspirin; Child, Preschool; Coronary Aneurysm; Dipyridamole; Drug Therapy, Combination | 1999 |
Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin.
Topics: Anti-Inflammatory Agents; Aspirin; Child; Child, Preschool; Drug Therapy, Combination; Glucocorticoi | 2000 |
Kawasaki disease: effect of treatment on coronary artery involvement.
Topics: Aspirin; Cephalexin; Child, Preschool; Coronary Angiography; Coronary Circulation; Coronary Disease; | 1979 |
Kawasaki disease in two African siblings.
Topics: Africa; Child; Female; Humans; Hydrocortisone; Infant; Lymphatic Diseases; Male; Mucocutaneous Lymph | 1979 |
Mucocutaneous lymph node syndrome in Calabar--a case report.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child, Preschool; Female | 1989 |
Efficacies and risks of aspirin in the treatment of the Kawasaki disease.
Topics: Aspirin; Child; Child, Preschool; Coronary Aneurysm; Humans; Immunization, Passive; Mucocutaneous Ly | 1987 |
Enhanced endothelial cell proliferation in acute Kawasaki disease (muco-cutaneous lymph node syndrome).
Topics: Antigen-Antibody Complex; Cell Division; Cells, Cultured; Chemical Fractionation; Child; Child, Pres | 1986 |